Tumor cells pose a challenge to the adaptive immune system, and its key cell types, T and B
cells, have frequently been associated with an improved prognosis. The success of immune …

The first anti-tumour necrosis factor (TNF) monoclonal antibody, infliximab (Remicade),
celebrated its 25th anniversary of FDA approval in 2023. Inhibitors of TNF have since proved …

Simple Summary Tertiary lymphoid structures (TLS) are anatomic entities that are similar to,
but distinct from, secondary lymphoid structures (eg, lymph nodes) that allow for a host's own …

Cancer immunotherapies have revolutionized the treatment of numerous cancers, with
exciting results often superior to conventional treatments, such as surgery and …

Hydrogels, a class of materials with a 3D network structure, are widely used in various
applications of therapeutic delivery, particularly cancer therapy. Micro and nanogels as …

Tertiary lymphoid structures (TLS) are clusters of immune cells that resemble and function
similarly to secondary lymphoid organs (SLOs). While TLS is generally associated with an …

The essential innate immunity effector cells, natural killer and dendritic cells, express
multiple plasma membrane-associated tumor necrosis factor (TNF) superfamily (TNFSF) …

Pancreatic ductal adenocarcinoma (PDA) is usually unresponsive to immunotherapeutic
approaches. However, tertiary lymphoid structures (TLS) are associated with favorable …

B cell immunity has a penetrating effect on human health and diseases. Therapeutics aiming
to modulate B cell immunity have achieved remarkable success in combating infections …

Glioblastoma is the most common and aggressive brain tumor, which is uniformly lethal due
to its extreme invasiveness and the absence of curative therapies. Immune checkpoint …